NCT00634985View on ClinicalTrials.gov

Safety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfully Treated With Nonsteroidal Anti-inflammatory Drugs

PHASE4CompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

November 30, 2002

Study Completion Date

December 31, 2003

Conditions

Migraine

Interventions

DRUG

eletriptan

40 mg oral tablet for migraine attack; additional 40 mg oral tablet \>2 hours from first dose if migraine reoccurred within 24 hours of achieving response

Trial Locations (6)

Unknown

Pfizer Investigational Site, Çapa

Pfizer Investigational Site, Gaziantep

Pfizer Investigational Site, Istanbul

Pfizer Investigational Site, Izmir

Pfizer Investigational Site, Samsun

Pfizer Investigational Site

All Listed Sponsors

lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00634985 - Safety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfully Treated With Nonsteroidal Anti-inflammatory Drugs | Biotech Hunter | Biotech Hunter